Latest Conference Articles

Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.

With encouraging overall response and disease control rates, lenvatinib plus pembrolizumab has the potential to be a frontline treatment option for non–clear cell renal cell carcinoma.

Data presented at ESMO 2022 showed GSK3326595, aPRMT5 inhibitor, to display efficacy and safety signals consistent with those that were previously reported in advanced solid tumors.

Ribociclib combined with endocrine therapy adds survival benefit when given to patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases.

The use of adagrasib in combination with cetuximab or alone elicted encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

The combination of belzutifan and cabozantinib was well tolerated in patients with treatment-naïve advanced clear cell renal cell carcinoma, according to findings presented at the 2022 ESMO Congress.

Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.

The combination of belzutifan and cabozantanib maintained antitumor activity in patients with advanced clear cell renal cell carcinoma who previously received immunotherapy.

The combination of enfortumab vedotin plus pembrolizumab led to a confirmed overall response rate of 64.5% in patients with metastatic urothelial cancer.

A presentation at ESMO 2022 explains the use of circulating tumor DNA as a tool which can predict outcomes for patients with diffuse large B-cell lymphoma.

The combination of orelabrutinib plus the R-CHOP regimen revealed a positive overall response rate of 86.4% when given to patients with non-germinal center B cell-like diffuse large B-cell lymphoma.

Patients with more than 2 tertiary lymphoid structures, high Ki-67, and PD-1 positivity had high response rates to nivolumab plus ipilimumab.

No statistically significant improvement in radiographic progression-free survival and overall survival was seen with pembrolizumab plus olaparib in metastatic castration-resistant prostate cancer.

The addition of 2 years of androgen-deprivation therapy to radiotherapy after radical prostatectomy improved metastasis-free survival and time to salvage therapy in patients with prostate cancer.

Tucatinib alone and with trastuzumab supported further investigation of each regimen in metastatic HER2-positive colorectal cancer.

The rate of 2-year overall survival was nearly doubled with atezolizumab vs vinorelbine or gemcitabine in advanced platinum-ineligible non–small cell lung cancer.

A reduced the risk for disease progression by 27% was seen with the combination of cabozantinib added to nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma.

Significant improvements in progression-free survival were seen with sotorasib compared with docetaxel in patients with KRAS G12C–mutated non–small cell lung cancer.

Neoadjuvant cemiplimab showed promising results in cutaneous squamous cell carcinoma with a near or complete disappearance of disease in almost 64% of patients set to undergo surgery.

Trastuzumab deruxtecan at 5.4mg/kg demonstrated clinically meaningful benefit in patients with HER2-mutated non–small cell lung cancer.

Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.

Androgen-deprivation therapy with the addition of apalutamide was effective when used in patients with high-risk biochemically relapsed prostate cancer.

A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.

At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.

Updated findings from the phase 3 ADAURA trial showed a significant disease-free survival improvement with the use of adjuvant osimertinib compared with placebo in patients with EGFR-mutated, stage I to IIIA non–small cell lung cancer.

A more tailored approach to treatment with PD-1 and CTLA-4 immune checkpoint blockade led to improved responses for patients with advanced renal cell carcinoma in both the first- and second-line settings, according to final results from the phase 2 TITAN-RCC trial.

Patient-reported outcomes from the DESTINY-Breast04 trial showed a quality-of-life benefit from treatment with trastuzumab deruxtecan compared with physician’s choice of therapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer.

Results from the phase 2 SWOG S181 study show that for patients given pembrolizumab in the neoadjuvant setting had a significant EFS benefit compared with adjuvant pembrolizumab.

Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.

Even after additional follow-up, the CLEAR trial showed a benefit for the combination of lenvatinib and pembrolizumab over sunitinib in patients with advanced clear cell renal cell carcinoma.